---
layout: default
title: Nitrofurantoin
description: "Nitrofurantoin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 115
evidence_level: L5
indication_count: 10
---

# Nitrofurantoin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Nitrofurantoinï¼šå¾ å°¿è·¯æ„ŸæŸ“ åˆ° é¡é¢¨æ¿•æ€§é—œç¯€ç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Nitrofurantoin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Nitrofurantoinï¼ˆæ·‹å¯è¼¸ï¼‰æ˜¯ä¸€ç¨®åˆæˆæŠ—èŒåŠ‘ï¼Œå°ˆé–€ç”¨æ–¼æ²»ç™‚å°¿è·¯æ„ŸæŸ“ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**é¡é¢¨æ¿•æ€§é—œç¯€ç‚ (rheumatoid arthritis)** æœ‰æ½›åœ¨é—œè¯ï¼Œä½†æ–‡ç»è­‰æ“šé¡¯ç¤ºé€™ä¸»è¦æ˜¯å…±ç—…é—œä¿‚æˆ–è—¥ç‰©ä¸è‰¯åæ‡‰å ±å‘Šï¼Œè€Œéæ²»ç™‚æ•ˆæœã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | å°¿è·¯æ„ŸæŸ“ï¼ˆè†€èƒ±ç‚ã€è…ç›‚ç‚ã€å°¿é“ç‚ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | rheumatoid arthritisã€autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndromeã€brain small vessel disease 1 with or without ocular anomaliesã€diabetic nephropathyã€brachydactyly-syndactyly syndromeã€colobomatous microphthalmia-rhizomelic dysplasia syndromeã€sclerosing cholangitisã€methemoglobinemia, alpha typeã€goutã€methemoglobinemia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.89% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Hold |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬å¯èƒ½æ˜¯å½ç›¸é—œï¼Ÿ

Nitrofurantoin é€šéæå‚·ç´°èŒ DNA å’ŒæŠ‘åˆ¶é…¶æ´»æ€§ç™¼æ®æ®ºèŒä½œç”¨ï¼Œå°é©è˜­æ°é™½æ€§å’Œé™°æ€§èŒå‡æœ‰æ•ˆã€‚å…¶ä½œç”¨å±€é™æ–¼å°¿è·¯ï¼Œå…¨èº«å¸æ”¶æœ‰é™ã€‚

**æ–‡ç»å›é¡§é¡¯ç¤ºï¼š**
- å¤šç¯‡æ–‡ç»æåŠ nitrofurantoin èˆ‡é¡é¢¨æ¿•æ€§é—œç¯€ç‚çš„é—œä¿‚ï¼Œä½†ä¸»è¦æ˜¯ï¼š
  1. **è—¥ç‰©æ€§è‚ºçº–ç¶­åŒ–**ï¼šNitrofurantoin æ˜¯å·²çŸ¥å¯å°è‡´è‚ºçº–ç¶­åŒ–çš„è—¥ç‰©ï¼Œé€™ä¹Ÿæ˜¯é¡é¢¨æ¿•æ€§é—œç¯€ç‚çš„ä½µç™¼ç—‡
  2. **å…±ç—…å ±å‘Š**ï¼šé¡é¢¨æ¿•æ€§é—œç¯€ç‚æ‚£è€…ä½¿ç”¨ nitrofurantoin æ²»ç™‚å°¿è·¯æ„ŸæŸ“çš„ç—…ä¾‹å ±å‘Š
  3. **æŠ—ç”Ÿç´ èˆ‡ RA æƒ¡åŒ–**ï¼šç ”ç©¶é¡¯ç¤ºæŸäº›æŠ—ç”Ÿç´ å¯èƒ½è§¸ç™¼ RA æƒ¡åŒ–

**ç¼ºä¹æ²»ç™‚è­‰æ“šï¼š**
- ç„¡è­‰æ“šé¡¯ç¤º nitrofurantoin å° RA æœ‰æŠ—ç™¼ç‚æˆ–å…ç–«èª¿ç¯€ä½œç”¨
- Nitrofurantoin ä¸»è¦å±€é™æ–¼å°¿è·¯ï¼Œä¸é©åˆå…¨èº«æ€§ç–¾ç—…æ²»ç™‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|---------|
| [31222078](https://pubmed.ncbi.nlm.nih.gov/31222078/) | 2019 | Journal Article | æŠ—ç”Ÿç´ ä½¿ç”¨èˆ‡ RA æƒ¡åŒ–çš„é—œä¿‚ï¼Œnitrofurantoin è¢«åˆ—ç‚ºç ”ç©¶è—¥ç‰©ä¹‹ä¸€ |
| [35145797](https://pubmed.ncbi.nlm.nih.gov/35145797/) | 2022 | Case Report | Methotrexate å’Œ nitrofurantoin äº¤äº’ä½œç”¨å°è‡´ä¸å¯é€†è‚ºçº–ç¶­åŒ– |
| [3335140](https://pubmed.ncbi.nlm.nih.gov/3335140/) | 1988 | Journal Article | RA æ‚£è€…ä½é™¢æ²»ç™‚é–“è³ªæ€§è‚ºçº–ç¶­åŒ–ï¼Œéƒ¨åˆ†èˆ‡ nitrofurantoin ç›¸é—œ |

é€™äº›æ–‡ç»é¡¯ç¤º nitrofurantoin èˆ‡ RA çš„é—œè¯ä¸»è¦æ˜¯**ä¸è‰¯åæ‡‰**ï¼ˆè‚ºçº–ç¶­åŒ–ï¼‰æˆ–**å…±ç—…æ²»ç™‚**ï¼Œè€Œéæ²»ç™‚æ•ˆæœã€‚

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | æ·‹å¯è¼¸ç‰‡ç­‰ | éŒ åŠ‘/è† å›Š | è…ç›‚ç‚ã€è†€èƒ±ç‚ã€å°¿é“ç‚ã€å°¿è·¯æ„ŸæŸ“ç—‡ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦å‘Šï¼š**
- **è‚ºæ¯’æ€§**ï¼šæ€¥æ€§ã€äºæ€¥æ€§å’Œæ…¢æ€§è‚ºåæ‡‰ï¼ŒåŒ…æ‹¬è‚ºçº–ç¶­åŒ–
- é•·æœŸä½¿ç”¨ï¼ˆ>6å€‹æœˆï¼‰å¢åŠ è‚ºçº–ç¶­åŒ–é¢¨éšª
- è‚æ¯’æ€§ï¼ˆç½•è¦‹ï¼‰
- ç¥ç¶“ç—…è®Šï¼ˆé•·æœŸä½¿ç”¨ï¼‰

**RA æ‚£è€…æ³¨æ„ï¼š**
- RA æœ¬èº«å¯å°è‡´é–“è³ªæ€§è‚ºç–¾ç—…
- åˆä½µä½¿ç”¨ methotrexate æœƒå¢åŠ è‚ºæ¯’æ€§é¢¨éšª
- ä¸å»ºè­° RA æ‚£è€…é•·æœŸä½¿ç”¨ nitrofurantoin


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Peripheral Nervous System Diseases** ğŸŸ¡ Moderate
- The use of nitrofurantoin has occasionally been associated with the development of peripheral neuropathy, which may be severe and irreversible.  Patients at risk include the elderly and those with renal impairment, anemia, diabetes mellitus, electrol...

**Respiratory Insufficiency** ğŸŸ¡ Moderate
- Chronic pulmonary reactions, generally in patients who have received continuous treatment for 6 months or longer have been reported with the use of nitrofurantoin.  Caution is recommended when prescribing this agent to patients with pulmonary dysfunc...

**Colitis** ğŸŸ¢ Minor
- Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomy...

**Glucosephosphate Dehydrogenase Deficiency** ğŸŸ¢ Minor
- Hemolytic anemia has been reported in patients treated with nitrofurantoin, primarily in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with nitrofurantoin should be avoided or administered cautiously in patients with G...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- The use of nitrofurantoin has rarely been associated with hepatotoxicity, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis.  Nitrofurantoin macrocrystals capsules are contraindicated in patients with a previou...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
æ–‡ç»åˆ†æé¡¯ç¤º nitrofurantoin èˆ‡é¡é¢¨æ¿•æ€§é—œç¯€ç‚çš„é—œè¯ä¾†è‡ªï¼šï¼ˆ1ï¼‰å…©è€…å…±åŒå°è‡´è‚ºçº–ç¶­åŒ–çš„å‰¯ä½œç”¨/ä½µç™¼ç—‡ï¼Œï¼ˆ2ï¼‰RA æ‚£è€…ä½¿ç”¨ nitrofurantoin æ²»ç™‚å°¿è·¯æ„ŸæŸ“çš„ç—…ä¾‹å ±å‘Šã€‚é€™æ˜¯çŸ¥è­˜åœ–è­œä¸­çš„å½ç›¸é—œï¼Œè€ŒéçœŸæ­£çš„æ²»ç™‚é—œä¿‚ã€‚æ­¤å¤–ï¼Œnitrofurantoin çš„å…¨èº«åˆ†å¸ƒæœ‰é™ï¼Œä¸é©åˆç”¨æ–¼å…¨èº«æ€§è‡ªé«”å…ç–«ç–¾ç—…ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ä¸å»ºè­°é€²ä¸€æ­¥æ¢ç´¢æ­¤é©æ‡‰ç—‡
- æ­¤é æ¸¬åæ˜ çš„æ˜¯å…±ç—…/ä¸è‰¯åæ‡‰é—œä¿‚ï¼Œè€Œéæ²»ç™‚æ½›åŠ›


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pitolisant]({{ "/drugs/pitolisant/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Iodixanol]({{ "/drugs/iodixanol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Nitrofurantoinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/nitrofurantoin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_nitrofurantoin,
  title = {Nitrofurantoinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/nitrofurantoin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
